Increasing its stake in Tergene Biotech from 60% to 80%
Aurobindo Pharma announced that Tergene Biotech is a 60:40 joint venture between the Company and promoters of Tergene. As agreed among the JV Partners, the Company will increase its stake in Tergene Biotech from 60% to 80% by subscribing additional 56,50,000 equity shares of Rs.10 each at par aggregating to Rs.5.65 crore.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
